Literature DB >> 7765983

In pursuit of the optimal fed-batch process for monoclonal antibody production.

T A Bibila1, D K Robinson.   

Abstract

Fed-batch culture currently represents the most attractive choice for large scale production for monoclonal antibodies (MAbs), due to its operational simplicity, reliability, and flexibility for implementation in multipurpose facilities. Development of highly productive cell lines, maximization of cell culture longevity, and maintenance of high specific antibody secretion rates through genetic engineering techniques, nutrition supplementation, waste product minimization, and control of environmental conditions are important for the design of high-yield fed-batch processes. Initially simple supplementation protocols have evolved into sophisticated serum-free multi-nutrient feeds that result in MAb titers on the order of 1-2 g/L. Limited research has been published to date on the effect of various culture parameters on potentially important quality issues, such as MAb glycosylation and stability. Although most fed-batch protocols to date have relied on relatively simple control schemes, increasingly sophisticated algorithms must be applied in order to take full advantage of the potentially additive effects of manipulating nutrient and environmental parameters to maximize fed-batch process productivity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7765983     DOI: 10.1021/bp00031a001

Source DB:  PubMed          Journal:  Biotechnol Prog        ISSN: 1520-6033


  27 in total

1.  Large scale transient expression with COS cells.

Authors:  H D Blasey; J P Aubry; G J Mazzei; A R Bernard
Journal:  Cytotechnology       Date:  1995-01       Impact factor: 2.058

2.  Comparison of viable cell concentration estimation methods for a mammalian cell cultivation process.

Authors:  M Aehle; R Simutis; A Lübbert
Journal:  Cytotechnology       Date:  2010-09-01       Impact factor: 2.058

Review 3.  Living with heterogeneities in bioreactors: understanding the effects of environmental gradients on cells.

Authors:  Alvaro R Lara; Enrique Galindo; Octavio T Ramírez; Laura A Palomares
Journal:  Mol Biotechnol       Date:  2006-11       Impact factor: 2.695

4.  Long-term Continuous Production of Monoclonal Antibody by Hybridoma Cells Immobilized in a Fibrous-Bed Bioreactor.

Authors:  Hui Zhu; Shang-Tian Yang
Journal:  Cytotechnology       Date:  2004-01       Impact factor: 2.058

5.  Effects of supplementation of various medium components on chinese hamster ovary cell cultures producing recombinant antibody.

Authors:  Do Yun Kim; Joon Chul Lee; Ho Nam Chang; Duk Jae Oh
Journal:  Cytotechnology       Date:  2005-01       Impact factor: 2.058

6.  A serum substitute for fed-batch culturing of hybridoma cells.

Authors:  Keisuke Shibuya; Ryoichi Haga; Masaru Namba
Journal:  Cytotechnology       Date:  2008-07-17       Impact factor: 2.058

7.  Effect of hypoosmotic pressure on cell growth and antibody production in recombinant Chinese hamster ovary cell culture.

Authors:  M S Lee; G M Lee
Journal:  Cytotechnology       Date:  2001-07       Impact factor: 2.058

8.  High yield of human monoclonal antibody produced by stably transfected Drosophila schneider 2 cells in perfusion culture using wave bioreactor.

Authors:  Lulan Wang; Hongxing Hu; Jianjun Yang; Feng Wang; Christian Kaisermayer; Paul Zhou
Journal:  Mol Biotechnol       Date:  2012-10       Impact factor: 2.695

9.  Bioprocess development for the production of mouse-human chimeric anti-epidermal growth factor receptor vIII antibody C12 by suspension culture of recombinant Chinese hamster ovary cells.

Authors:  Suwen Hu; Lei Deng; Huamao Wang; Yingping Zhuang; Ju Chu; Siliang Zhang; Zhonghai Li; Meijin Guo
Journal:  Cytotechnology       Date:  2011-02-05       Impact factor: 2.058

Review 10.  Current state and recent advances in biopharmaceutical production in Escherichia coli, yeasts and mammalian cells.

Authors:  Aleš Berlec; Borut Strukelj
Journal:  J Ind Microbiol Biotechnol       Date:  2013-02-06       Impact factor: 3.346

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.